{"cluster": 36, "subcluster": 17, "abstract_summ": "Jaktinib hydrochloride has great potential for the treatment of patients with coronavirus disease 2019 (COVID-19).Coronavirus disease-2019 (COVID-19) severity appears to parallel the host immune response, with a subset of patients developing COVID-19 cytokine storm syndrome (CSS).(1) Serum inflammatory cytokines are elevated in COVID-19,(2-5) and interleukin (IL)-6 appears to play a central role in COVID-19 related CSS.(6-8) Based on the success of IL-6 receptor blockade for chimeric antigen receptor T-cell therapy associated cytokine release syndrome (CAR T-cell CRS), similar strategies using tocilizumab are being investigated in COVID-19.A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a \u201cCytokine Storm Syndrome\u201d (CSS).In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS).Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS.Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS.The current treatment for cytokine storms is limited, so the international medical community is focusing on a specific and effective remedy.", "title_summ": "Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes", "title_abstract_phrases": "Coronavirus disease-2019 (COVID-19) severity appears to parallel the host immune response, with a subset of patients developing COVID-19 cytokine storm syndrome (CSS).(1) Serum inflammatory cytokines are elevated in COVID-19,(2-5) and interleukin (IL)-6 appears to play a central role in COVID-19 related CSS.(6-8) Based on the success of IL-6 receptor blockade for chimeric antigen receptor T-cell therapy associated cytokine release syndrome (CAR T-cell CRS), similar strategies using tocilizumab are being investigated in COVID-19.Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromesA subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a \u201cCytokine Storm Syndrome\u201d (CSS).Jaktinib hydrochloride has great potential for the treatment of patients with coronavirus disease 2019 (COVID-19).Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS).Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a serious public health threat to the whole world, and the number of infected is still rising dramatically at this moment.Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS."}